Improved detection rate of cytogenetic abnormalities in chronic lymphocytic leukemia and other mature B-cell neoplasms with use of CpG-oligonucleotide DSP30 and interleukin 2 stimulation

American Journal of Clinical Pathology

Volumn 139, Issue 5, 2013, Pages 662-669

  Shi, Min ^a   Cipollini, Matthew J ^a   Crowley Bish, Patricia A ^a   Higgins, Anne W ^a   Yu, Hongbo ^a   Miron, Patricia M ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

B cell lymphoma; CpG oligonucleotide DSP30; Cytogenetics

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 2;

ARTICLE; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETIC ABNORMALITY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MATURE B CELL NEOPLASM; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

BONE MARROW CELLS; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; CPG ISLANDS; CYTOGENETICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METAPHASE; OLIGONUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 84878057462     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP7G4VMYZJQVFI     Document Type: Article

References (23)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052-1057.
2. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
3. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006;24:969-975.
4. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
5. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92:382-388.
6. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720-724.
7. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442-2451.
8. Heerema NA, Byrd JC, Dal Cin PS, et al. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010;203:134-140.
9. Muthusamy N, Breidenbach H, Andritsos L, et al. Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genet. 2011;204:77-83.
10. Put N, Konings P, Rack K, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study. Genes Chromosomes Cancer. 2009;48:843-853.
11. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol. 2000;28:558-568.
12. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000;95:999-1006.
13. Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol. 2001;167:3555-3558.
14. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745.
15. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via speciesspecific CpG motif recognition. Proc Natl Acad Sci U S A. 2001;98:9237-9242.
16. Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I. Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors. Ann Hematol. 2010;89:1125-1132.
17. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol. 2001;69:81-88.
18. Reid GS, She K, Terrett L, et al. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood. 2005;105:3641-3647.
19. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549.
20. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742-751.
21. Hagenkord JM, Monzon FA, Kash SF, et al. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. J Mol Diagn. 2010;12:184-196.
22. Dierlamm J, Michaux L, Criel A, et al. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet. 1997;94:27-35.
23. Juliusson G, Robert KH, Ost A, et al. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood. 1985;65:134-141.